BioSpace News Archive

Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, reported its financial results for the second quarter and six months ended June 30, 2021, and provided a corporate update.

MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the launch of its pro-bono support program aimed at advancing research for ultra-rare diseases. Within this program, MMS will select from patient advocacy groups with demonstrable need and will provide complimentary regulatory assistance.

miR Scientific, LLC announces the appointment of Erik Johnson, a seasoned leader in pharma and oncology, as Chief Operating Officer.

Fujifilm Corporation, a global medical imaging device provider, announced its AI-powered product for analyzing chest X-ray ‘CXR-AID’ will be commercially available across Japan.

FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, today announced the appointment of Hamid Khoja, Ph.D. as Chief Scientific Officer.

The global point of care diagnostics market is expected to reach US$ 70.89 Bn in 2027 from US$ 26.60 Bn in 2018.

The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade.

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract about the neurology platform NeuroRestore, its link to BDNF/TrkB signalling and potential therapeutic role in depression, has been accepted for presentation at the ECNP 2021 conference.

The global E-Health Market was pegged at $74.47 billion in 2019 and is expected to hit $230.64 billion by 2027, registering a CAGR of 14.5% from 2020 to 2027.

Rise in prevalence of hydrocephalus, growth in adoption of advanced programmable valves, and surge in incidences of neurological disorder drive the growth of the global hydrocephalus shunts market.